JP2022502055A5 - - Google Patents
Info
- Publication number
- JP2022502055A5 JP2022502055A5 JP2021517350A JP2021517350A JP2022502055A5 JP 2022502055 A5 JP2022502055 A5 JP 2022502055A5 JP 2021517350 A JP2021517350 A JP 2021517350A JP 2021517350 A JP2021517350 A JP 2021517350A JP 2022502055 A5 JP2022502055 A5 JP 2022502055A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- guide
- composition
- seq
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862738956P | 2018-09-28 | 2018-09-28 | |
| US62/738,956 | 2018-09-28 | ||
| US201962834334P | 2019-04-15 | 2019-04-15 | |
| US62/834,334 | 2019-04-15 | ||
| US201962841740P | 2019-05-01 | 2019-05-01 | |
| US62/841,740 | 2019-05-01 | ||
| PCT/US2019/053423 WO2020069296A1 (en) | 2018-09-28 | 2019-09-27 | Compositions and methods for lactate dehydrogenase (ldha) gene editing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022502055A JP2022502055A (ja) | 2022-01-11 |
| JP2022502055A5 true JP2022502055A5 (cg-RX-API-DMAC7.html) | 2022-09-30 |
Family
ID=68296656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517350A Pending JP2022502055A (ja) | 2018-09-28 | 2019-09-27 | 乳酸デヒドロゲナーゼ(ldha)遺伝子編集のための組成物及び方法 |
Country Status (15)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220004648A (ko) * | 2019-03-28 | 2022-01-11 | 인텔리아 테라퓨틱스, 인크. | Ttr 가이드 rna, 및 rna-가이드 dna 결합제를 암호화하는 폴리뉴클레오티드를 포함하는 조성물 및 방법 |
| MX2023004371A (es) | 2020-10-14 | 2023-07-26 | George Mason Res Foundation Inc | Lípidos ionizables, y métodos de fabricación y uso de los mismos. |
| WO2022256655A2 (en) * | 2021-06-04 | 2022-12-08 | Arbor Biotechnologies, Inc. | Gene editing systems comprising an rna guide targeting lactate dehydrogenase a (ldha) and uses thereof |
| EP4423271A2 (en) | 2021-10-28 | 2024-09-04 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
| WO2023122433A1 (en) * | 2021-12-22 | 2023-06-29 | Arbor Biotechnologies, Inc. | Gene editing systems targeting hydroxyacid oxidase 1 (hao1) and lactate dehydrogenase a (ldha) |
| IL314482A (en) | 2022-02-02 | 2024-09-01 | Regeneron Pharma | Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease |
| CN114657181B (zh) * | 2022-04-01 | 2023-08-25 | 安徽大学 | 一种靶向H1.4的sgRNA以及H1.4基因编辑方法 |
| WO2023212677A2 (en) | 2022-04-29 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Identification of tissue-specific extragenic safe harbors for gene therapy approaches |
| WO2023235725A2 (en) | 2022-05-31 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Crispr-based therapeutics for c9orf72 repeat expansion disease |
| WO2023235726A2 (en) | 2022-05-31 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Crispr interference therapeutics for c9orf72 repeat expansion disease |
| CN120659627A (zh) | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体(tfr)介导的脑和肌肉递送的组合物和方法 |
| KR20250075694A (ko) | 2022-09-28 | 2025-05-28 | 리제너론 파마슈티칼스 인코포레이티드 | 세포 기반 요법을 강화하기 위한 항체 저항성 변형 수용체 |
| AU2023371614A1 (en) | 2022-11-04 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
| AU2023379457A1 (en) | 2022-11-14 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
| IL326018A (en) | 2023-07-28 | 2026-03-01 | Regeneron Pharma | Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease |
| AU2024315073A1 (en) | 2023-07-28 | 2026-01-22 | Regeneron Pharmaceuticals, Inc. | Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion |
| AR133384A1 (es) | 2023-07-28 | 2025-09-24 | Regeneron Pharma | Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida |
| EP4771049A1 (en) | 2023-08-28 | 2026-07-08 | Regeneron Pharmaceuticals, Inc. | Cxcr4 antibody-resistant modified receptors |
| WO2025045247A1 (en) * | 2023-08-31 | 2025-03-06 | Geneditbio Limited | Nucleic acids encoding crispr-associated proteins and uses thereof |
| EP4771154A2 (en) | 2023-09-01 | 2026-07-08 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025162435A1 (en) * | 2024-02-02 | 2025-08-07 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treatment of liver disease |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025235388A1 (en) | 2024-05-06 | 2025-11-13 | Regeneron Pharmaceuticals, Inc. | Transgene genomic identification by nuclease-mediated long read sequencing |
| WO2025265017A1 (en) | 2024-06-20 | 2025-12-26 | Regeneron Pharmaceuticals, Inc. | Ass1 gene insertion for the treatment of citrullinemia type i |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| ATE515510T1 (de) | 1991-12-24 | 2011-07-15 | Isis Pharmaceuticals Inc | Durch dna-abschnitte unterbrochene modifizierte oligonukleotide |
| EP0760008A1 (en) | 1994-05-19 | 1997-03-05 | Dako A/S | Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| PT2931898E (pt) | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais |
| IL308158A (en) | 2012-12-17 | 2023-12-01 | Harvard College | Rna-guided human genome engineering |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| WO2015200555A2 (en) | 2014-06-25 | 2015-12-30 | Caribou Biosciences, Inc. | Rna modification to engineer cas9 activity |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| US10351854B2 (en) * | 2014-10-10 | 2019-07-16 | Dicerna Pharmaceuticals, Inc. | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
| AU2016226077B2 (en) | 2015-03-03 | 2021-12-23 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases with altered PAM specificity |
| WO2017136794A1 (en) | 2016-02-03 | 2017-08-10 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
| ES3030658T3 (en) | 2016-03-30 | 2025-07-01 | Intellia Therapeutics Inc | Lipid nanoparticle formulations for crispr/cas components |
| EP3452080A4 (en) * | 2016-05-02 | 2019-10-09 | The Regents of the University of California | MAMMALIAN CELLS WITHOUT LACTATE DEHYDROGENASE ACTIVITY |
| EP3551757A1 (en) | 2016-12-08 | 2019-10-16 | Intellia Therapeutics, Inc. | Modified guide rnas |
-
2019
- 2019-09-27 BR BR112021005718-8A patent/BR112021005718A2/pt not_active IP Right Cessation
- 2019-09-27 WO PCT/US2019/053423 patent/WO2020069296A1/en not_active Ceased
- 2019-09-27 KR KR1020217012025A patent/KR20210086621A/ko not_active Withdrawn
- 2019-09-27 SG SG11202102660RA patent/SG11202102660RA/en unknown
- 2019-09-27 JP JP2021517350A patent/JP2022502055A/ja active Pending
- 2019-09-27 TW TW108135340A patent/TW202028460A/zh unknown
- 2019-09-27 CN CN201980076179.XA patent/CN113056559A/zh active Pending
- 2019-09-27 CA CA3114425A patent/CA3114425A1/en active Pending
- 2019-09-27 AU AU2019347517A patent/AU2019347517A1/en not_active Withdrawn
- 2019-09-27 MX MX2021003457A patent/MX2021003457A/es unknown
- 2019-09-27 EP EP19790921.1A patent/EP3856901A1/en active Pending
-
2021
- 2021-03-16 IL IL281529A patent/IL281529A/en unknown
- 2021-03-25 US US17/212,901 patent/US20210222173A1/en not_active Abandoned
- 2021-03-26 PH PH12021550686A patent/PH12021550686A1/en unknown
- 2021-04-23 CO CONC2021/0005231A patent/CO2021005231A2/es unknown
-
2025
- 2025-05-16 US US19/210,426 patent/US20260035697A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021531804A5 (cg-RX-API-DMAC7.html) | ||
| JP2024178237A (ja) | 修飾されたガイドrna | |
| JP2022501040A5 (cg-RX-API-DMAC7.html) | ||
| JP6799058B2 (ja) | アレル選択的な遺伝子編集およびその使用 | |
| US5744460A (en) | Combination for treatment of proliferative diseases | |
| JP2022527108A5 (cg-RX-API-DMAC7.html) | ||
| JP2022512703A5 (cg-RX-API-DMAC7.html) | ||
| JP2021526804A5 (cg-RX-API-DMAC7.html) | ||
| JP2018520685A (ja) | B型肝炎ウイルスに対する組成物および薬剤ならびにその使用 | |
| JP2023502038A5 (cg-RX-API-DMAC7.html) | ||
| JP2017516461A (ja) | 遺伝子サイレンシングにおいて低下したoff−target効果を有するunaオリゴマー | |
| CZ2003848A3 (cs) | Způsob léčby poruch spojených s bcl-2 za použití antisense oligomerů bcl-2 | |
| JP2024516356A5 (cg-RX-API-DMAC7.html) | ||
| JP2022533358A5 (cg-RX-API-DMAC7.html) | ||
| IL277970B2 (en) | Oligomeric compounds comprising modified oligonucleotides and conjugated groups for use in the treatment of end-stage renal disease, chronic kidney disease and coronary artery disease | |
| JP2022520986A5 (cg-RX-API-DMAC7.html) | ||
| JP2022518384A5 (cg-RX-API-DMAC7.html) | ||
| JP2019512543A (ja) | β−カテニン関連疾患又は障害の治療のための組成物及び方法 | |
| JP2013504603A5 (cg-RX-API-DMAC7.html) | ||
| CN119137272A (zh) | 血管紧张素原调节组合物和其使用方法 | |
| JP2002512792A (ja) | インスリン様増殖因子iiアンチセンスオリゴヌクレオチド配列および細胞増殖を調節するためのその使用方法 | |
| JP5406024B2 (ja) | Bcl−XL特異的siNAを用いる癌治療法 | |
| TW201038278A (en) | Rnai molecule for thymidylate synthase and use thereof | |
| JP2024543195A5 (cg-RX-API-DMAC7.html) | ||
| JP6437930B2 (ja) | 悪性胸膜中皮腫を治療するためのマイクロrnaを基にしたアプローチ |